ストックスクリーナーアプリを入手
60.77
1.81%
-1.12
アフターアワーズ：
59.96
-0.81
-1.33%
前日終値:
$61.89
開ける：
$62.445
24時間の取引高:
1.67M
Relative Volume:
0.96
時価総額：
$5.98B
収益：
$4.10M
当期純損益:
$-568.53M
株価収益率:
-9.783
EPS:
-6.2118
ネットキャッシュフロー:
$-401.18M
1週間 パフォーマンス:
+11.42%
1か月 パフォーマンス:
+17.23%
6か月 パフォーマンス:
+4.79%
1年 パフォーマンス:
+18.71%
1日の値動き範囲:
$58.58
$62.80
1週間の範囲:
$54.56
$63.45
52週間の値動き範囲:
$44.12
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Compare CRSP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
60.77 | 6.10B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | JP Morgan | Overweight |
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - Yahoo Finance
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now - The Motley Fool
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
CRSPCRISPR Therapeutics AG Options - Finviz
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential - Investing.com
Does CRISPR Therapeutics’ (CRSP) Russell Index Debut Quietly Reframe Its Biotech Growth Narrative? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices - FXEmpire
CRISPR Therapeutics (CRSP) Is Up 11.3% After Broad Russell Growth Index Inclusion Has The Bull Case Changed? - Yahoo Finance
Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment - Seeking Alpha
CRSP News | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
CRSP Stock Pops As Morgan Stanley Doubles Price Target - timothysykes.com
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - Yahoo Finance
CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2500 Growth Benchmark - marketscreener.com
ETFs Investing in CRISPR Therapeutics AG Stocks - TradingView
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Growth Benchmark - marketscreener.com
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000E Growth Benchmark - marketscreener.com
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
Price to sales forward of CRISPR Therapeutics AG – DUS:1CG - TradingView
Price to book forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
Price to earnings forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Price to book forward of CRISPR Therapeutics AG – DUS:1CG - TradingView
Enterprise value to revenue forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
The Best Stocks to Invest $1,000 in Right Now - AOL.com
Enterprise value to revenue forward of CRISPR Therapeutics AG – DUS:1CG - TradingView
Enterprise value to EBITDA forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
Enterprise value to EBIT forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
CRISPR Therapeutics AG (CRSP) advances while market declines: Some information for investors - MSN
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Is CRISPR Therapeutics (CRSP) Finally Ready for Prime Time After Casgevy's Initial Success - Kavout | AI
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM) - Seeking Alpha
CRISPR Therapeutics AG Actuals & Estimates (NASDAQ:CRSP) - TradingView
CRSP Forecast — Price Target — Prediction for 2027 - TradingView
3 Companies Redefining Healthcare Innovation - Seeking Alpha
CRISPR Therapeutics AG (CRSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CRISPR Therapeutics clears a key chart level, shares trade higher on NASDAQ - Ad-hoc-news.de
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
CRISPR Therapeutics (CRSP) TD Cowen 46th Annual Health Care Conference Summary - Quartr
CRISPR Therapeutics (CRSP) Stock Could Be 69.5% Below Fair Value After Recent Gains - Sahm
CRISPR Therapeutics StockWeekly review against gene-editing peers - AD HOC NEWS
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it - MSN
CRISPR Therapeutics Faces Market Challenges Amid Progress - Intellectia AI
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year - The Motley Fool
CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRISPR Therapeutics AG (CRSP) Institutional Confidence - TradingKey
CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):